Introduction
============

In Japan, more than 12 million people are believed to suffer from diabetes ([@b7-co-2-233]). The most common complication of diabetes is diabetic retinopathy, which is the leading cause of legal blindness among working-age adults in Japan. The functional components of diabetic retinopathy are vascular permeability and neural cell death. Recent studies have shown that most of the neural cell death in retinas associated with diabetic retinopathy is due to apoptosis ([@b3-co-2-233]; [@b17-co-2-233]).

Some glial cells are well known to maintain survival of neural cells by production of various cytokines. Recently we reported that retinoic acid receptor stimulants such as all-trans-retinoic acid (ATRA) and 4-\[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carboxamido\] benzoic acid (Am580) improve diabetic retinopathy via changes of cytokine production in glial cells ([@b18-co-2-233]; [@b14-co-2-233]). In this study, we investigated whether RAs had any effect on apoptosis during the development of diabetic retinopathy.

Material and methods
====================

To determine whether RAs had any effect on apoptosis during the development of diabetic retinopathy, 32 C57BL/6 male mice (5 weeks old, CLEA JAPAN, Tokyo, Japan) were housed and diabetes was induced in twenty-four mice by intra peritoneal (i.p.) injection of 40 mg/kg streptozotocin (STZ; Sigma, St Louis, MO) dissolved in 0.01M trisodium citrate buffer (pH 4.5) for 5 consecutive days. The cut-off levels in mice used to diagnose diabetes were more than 200 mg/dl in blood sugar measured using Gluco-card (ARKRAY, Kyoto, Japan) and positive urinal sugar measured using Rub-stick (Bayer, Leverkusen, Germany). Six weeks after the verification of diabetes, when the blood--retinal barrier breakdown was progressing as previously described ([@b14-co-2-233]), mice were treated with 1.0 mg/kg ATRA every day (seven mice, 14 eyes) or 3.75 mg/kg Am580 every other day (nine mice, 18 eyes) for 1 week ([@b14-co-2-233], [@b15-co-2-233]). Control mice (eight mice, 16 eyes) were i.p. injected with a solvent alone (250 μl of DMSO; Sigma). After the mice were sacrificed by dislocating the cervical vertebrae, enucleated mouse eyeballs were fixed in 1% paraformaldehyde/phosphate-buffered saline overnight. After the eyeballs were sliced in horizontal sections and flat-mounted onto a slide, TdT-dUTP terminal nick-end labeling (TUNEL) was performed using the In Situ Cell Death Detection Kit, Fluorescein (Roche, Basel, Switzerland). Using a laser-scanning confocal microscope (MRC 1024; Bio-Rad, Hercules, CA), the numbers of apoptotic cells in the retinas of all 64 eyes of the 32 mice were counted in 3\~4 views of the retinas approximately 100 μm from the center of the optic nerve disk in each eye at the same magnification (×20) and averaged. All animal experiments followed the specifications of the Guidelines for Animal Experiments of Sapporo Medical University School of Medicine. All values are expressed as mean and SD. Data were statistically analyzed with the Fisher test for comparison of four groups. The levels of statistical significance was set at p \< 0.05.

Results
=======

RAs inhibited the apoptosis during the development of diabetic retinopathy. To demonstrate this, we treated diabetic mice with ATRA or Am580 and measured apoptosis in the retina by TUNEL assay. Many apoptotic cells were observed in the retinas of the eight control diabetic mice (cell counts; max 60, minimum 30, mean value and SD: 37.8 ± 6.9), whereas when 16 diabetic mice were treated with ATRA or Am580, the number of apoptotic cells markedly decreased (cell counts; max 23, minimum 5, mean value and SD: 9.9 ± 6.4 in seven ATRA-treated diabetic mice and max 20, minimum 5, mean value and SD: 9.8 ± 5.9 in nine Am580-treated diabetic mice), and the level was suppressed nearly to the control level (cell counts; max 8, minimum 0, mean value and SD: 6.3 ± 2.6 in eight control mice) ([Figures 1A and B](#f1-co-2-233){ref-type="fig"}).

Discussion
==========

In this study, we demonstrated a marked decrease of apoptosis during the development of diabetic retinopathy after treatment with RAs, though the mechanisms by which this occurred have not yet been clarified. RA, an essential signaling molecule throughout life ([@b10-co-2-233]; [@b6-co-2-233]), could play an important role in the induction of glial cell line-derived neurotrophic factor (GDNF) in glial cells ([@b18-co-2-233]; [@b14-co-2-233]). GDNF is a neurotrophic and differentiation factor in the retina ([@b8-co-2-233]; [@b18-co-2-233]; [@b11-co-2-233]; [@b16-co-2-233]; [@b20-co-2-233]) as well as the central nervous system ([@b9-co-2-233]; [@b4-co-2-233]). Therefore one possible explanation is that RAs protect retinal cells in diabetic retinopathy by inducing GDNF production in glial cells in the retina ([@b14-co-2-233], [@b15-co-2-233]). GDNF affects a wide variety of signaling pathways ([@b5-co-2-233]; [@b19-co-2-233]; [@b1-co-2-233]) and there are many signaling pathways of apoptosis in retinal cells ([@b2-co-2-233]). Judging from the distribution of apoptosis in the retina, however, we cannot say anything about which cell type preferentially fell into apoptosis or which cell type was prevented from doing so by RAs, though several reports suggest that apoptosis in the retina preferentially occurs in retinal ganglion cells with photoreceptors ([@b8-co-2-233]; [@b20-co-2-233]).

Considering the observations of this study, we would like to make two proposals. One is that RAs are promising drugs for diabetic ophthalmic disease because they have anti-cataractogenic effects for diabetic cataracts ([@b15-co-2-233]), blood--retinal barrier-protective effects for vascular integrity ([@b12-co-2-233]; [@b14-co-2-233]), and neuroprotective effects against apoptosis in diabetic retinopathy. The other is that glial cells in the retina can be a new target for treating the retinopathy. Although we i.p. injected RAs, another drug delivery assay such as intravitreal injections will be examined to make RAs more effective on glial cells. Future work along the lines of our proposals might provide a fundamental understanding of the treatment effects of RAs and the treatment targets of glial cells in the development of diabetic ophthalmic diseases. RAs might increase neurotrophic cytokines such as GDNF in glial cells, contributing to decreased apoptosis during the development of diabetic retinopathy. Hopefully, this study will help to improve the outcomes of patients with diabetes.

![RAs inhibited the apoptosis during the development of diabetic retinopathy. **A** and **B**, Apoptosis of retinal cells in retina. (**A**, apoptotic cell counts, TdT-dUTP terminal nick-end labeling assay. **B**, laser-scanning confocal analysis.)\
**Abbreviations:** Ctrl, control mice; ATRA, all-trans-retinoic acid (ATRA)-treated diabetic mice; Am580, Am580-treated diabetic mice; DM, diabetic mice.\
**Notes:** \*\*p \< 0.01 Scale bars: 25 μm. The choroid (C), retinal pigment epithelium (RPE), outer nuclear layer (ONL), outer plexiform layer (OPL), inner nuclear layer (INL), inner plexiform layer (IPL), and the ganglion cell layer (GCL) are labeled in the micrograph.](co-2-233f1){#f1-co-2-233}
